Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development

Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business
Development

WHIPPANY, N.J., Jan. 26 /PRNewswire/ -- Adding to its strong executive team,
Halo Pharmaceutical today announced the addition of Allen M. Rosenston, a
thirty-five year pharmaceutical industry veteran, as Halo's new Vice President
of Business Development. Al comes to Halo from a long and distinguished
career at Abbott Laboratories where he held diverse roles in operations,
business development, and related business functions. "The addition of Al to
the Halo business development team is a significant achievement. Al has deep
experience within the pharmaceutical industry. He developed Abbott's domestic
Contract Pharmaceutical Manufacturing Business Unit and, at the time of his
retirement, he was responsible for the global finished goods contract
manufacturing business," according to Mohd Asif, Halo's Chief Financial
Officer.

Al comes to Halo shortly after Halo's acquisition of its Whippany, NJ
facility, a facility which has been producing various dosage forms for 35
years. "I am thrilled to be part of the Halo Pharmaceutical team, and to
build on the legacy of this outstanding facility and group of talented people
with an average seniority of over 20 years. Based on my discussions with the
new Halo team, this is a unique opportunity to create a world-class
pharmaceutical services company right in the heart of New Jersey. Maintaining
focus on quality, service, and compliance, along with the flexible
manufacturing capabilities of the Whippany facility, will create a high-level
of interest with prospective customers. I anticipate us to be highly
competitive when overall service value is assessed."

Halo capabilities include an impressive array of formulation services,
operations for the aseptic filling of topical ointments, solid dosage forms
(tablets and capsules), liquids, suppositories, associated packaging (tablet,
powder, liquids and HUD) and ample laboratory space for formulation
development, pre-clinical and clinical supplies and support of commercial
operations. An additional asset is the site's capability to manufacture
controlled substances (C2-C5) and an API manufacturing unit with an
outstanding track-record of meeting DEA requirements.

Al joined Halo on January 5, 2009, and can be reached at
arosenston@halopharma.com or at 973-428-4087.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service,
specialty pharmaceutical company, offering state-of-the-art contract
manufacturing, early stage formulation development and laboratory services to
the pharmaceutical and related industries. Halo is currently a supplier of
choice to a number of large and medium size brand pharmaceutical companies for
important lifecycle products. Contract manufacturing capabilities include the
ability to conduct aseptic filling, granulation, blending, tableting, coating,
packaging, and related warehousing operations. Halo Pharmaceutical is a
privately-held company.

SOURCE Halo Pharmaceutical

Douglas K. Kollmorgen, President, +1-973-428-4011, dkollmorgen@halopharma.com,
or Mohd Asif, Chief Financial Officer, +1-973-428-4013, masif@halopharma.com,
both of Halo Pharmaceutical